Reykjavik, ICELAND, March 9, 2005 — deCODE genetics (Nasdaq: DCGN) today announced that it has begun enrolling subjects in a Phase I clinical trial for DG041, the company's developmental compound for the treatment of atherosclerosis of the extremeties, commonly known as peripheral
arterial occlusive disease (PAOD).
Localization of a Gene for Peripheral
Arterial Occlusive Disease to Chromosome 1p31.
Not exact matches
Occlusive thrombi arise in mammals but not birds in response to
arterial injury: evolutionary insight into human cardiovascular disease.
Arteriosclerosis obliterans is an
occlusive («blocking»)
arterial disease that most commonly affects the abdominal aorta as well as both the small and medium sized arteries of the lower extremities.